Insulin analogues offer different pharmacokinetic profiles that allow insulin needs to be matched more closely, enable more convenient dosing regimens, and, in some cases, reduce the rate of adverse events.10 Newer treatments for T2D—sodium-glucose cotransporter 2 inhibitors (SGLT2Is) and glucagonlike peptide 1 agonists (GLP1As)—are now recommended for first-line treatment of T2D for patients with additional cardiovascular risk factors or obesity, independent of metformin use.11 The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.